[{"id":"d4921ecb-dbf8-4a8b-a82b-331ac066876f","acronym":"ACHIEVE Study","url":"https://clinicaltrials.gov/study/NCT06096844","created_at":"2023-10-24T15:13:40.333Z","updated_at":"2025-02-25T12:38:45.622Z","phase":"Phase 3","brief_title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","source_id_and_acronym":"NCT06096844 - ACHIEVE Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 304","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-24"},{"id":"868ab017-feca-462a-908a-0cf81a5b86b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310007","created_at":"2021-01-18T20:53:46.863Z","updated_at":"2025-02-25T16:37:47.177Z","phase":"Phase 2","brief_title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04310007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"6843c310-89f3-4a46-822e-007bc52f641b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420220","created_at":"2022-06-15T15:55:24.895Z","updated_at":"2024-07-02T16:35:06.663Z","phase":"Phase 2","brief_title":"Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05420220","lead_sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • erfonrilimab (KN046)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":" Primary completion: 05/29/2027","primary_completion_date":" 05/29/2027","study_txt":" Completion: 12/26/2027","study_completion_date":" 12/26/2027","last_update_posted":"2024-05-01"},{"id":"86efeb90-aaeb-41cd-9924-e0e905a3f738","acronym":"","url":"https://clinicaltrials.gov/study/NCT06055465","created_at":"2023-09-26T16:12:30.730Z","updated_at":"2024-07-02T16:35:16.949Z","phase":"Phase 2","brief_title":"Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06055465","lead_sponsor":"Chinese University of Hong Kong","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/28/2024","start_date":" 02/28/2024","primary_txt":" Primary completion: 12/30/2028","primary_completion_date":" 12/30/2028","study_txt":" Completion: 12/30/2029","study_completion_date":" 12/30/2029","last_update_posted":"2024-02-29"},{"id":"7eec8313-ce6d-47bc-92b7-e0a3b9ab9f7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03468985","created_at":"2021-01-18T17:05:50.225Z","updated_at":"2024-07-02T16:35:33.350Z","phase":"Phase 2","brief_title":"Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03468985","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative","tags":["EGFR • PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 05/09/2022","primary_completion_date":" 05/09/2022","study_txt":" Completion: 12/21/2022","study_completion_date":" 12/21/2022","last_update_posted":"2023-10-17"},{"id":"0b05481d-c3c1-4ad2-939c-6638e0bf26e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01068587","created_at":"2021-01-18T04:12:43.648Z","updated_at":"2025-02-25T13:15:36.669Z","phase":"Phase 1/2","brief_title":"MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy","source_id_and_acronym":"NCT01068587","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • foretinib (GSK1363089)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/21/2010","start_date":" 01/21/2010","primary_txt":" Primary completion: 03/21/2014","primary_completion_date":" 03/21/2014","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"6d25f6ec-c245-494d-974c-aac69b9a2c8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04012619","created_at":"2021-01-18T19:42:40.125Z","updated_at":"2024-07-02T16:35:41.072Z","phase":"Phase 1","brief_title":"Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer","source_id_and_acronym":"NCT04012619","lead_sponsor":"Sichuan University","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR negative","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Focus V (anlotinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2023-08-03"},{"id":"8d30dabf-c8c2-40f3-afe8-443d1be54740","acronym":"","url":"https://clinicaltrials.gov/study/NCT05842018","created_at":"2023-05-03T14:04:30.275Z","updated_at":"2024-07-02T16:35:49.079Z","phase":"Phase 2","brief_title":"Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)","source_id_and_acronym":"NCT05842018","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-05-03"},{"id":"0571b3b6-6285-4835-ab7e-a7fe6fcc54ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02942095","created_at":"2021-01-18T14:26:45.911Z","updated_at":"2025-02-25T14:50:19.404Z","phase":"Phase 1","brief_title":"Study of Ixazomib and Erlotinib in Solid Tumors","source_id_and_acronym":"NCT02942095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR T790M • KRAS G12 • EGFR positive • KRAS G13 • EGFR negative","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR T790M • KRAS G12 • EGFR positive • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Ninlaro (ixazomib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 12/07/2022","primary_completion_date":" 12/07/2022","study_txt":" Completion: 12/07/2022","study_completion_date":" 12/07/2022","last_update_posted":"2023-04-18"},{"id":"d6b419b3-2bb1-4e8d-8092-d15b16a83024","acronym":"CIRCULAR","url":"https://clinicaltrials.gov/study/NCT04912687","created_at":"2021-06-03T15:59:57.953Z","updated_at":"2025-02-25T14:59:53.818Z","phase":"","brief_title":"Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients","source_id_and_acronym":"NCT04912687 - CIRCULAR","lead_sponsor":"Institut Bergonié","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive • EGFR negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive • EGFR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-03-01"},{"id":"0b6d3060-8f22-49b8-8ccf-8539c20c6118","acronym":"","url":"https://clinicaltrials.gov/study/NCT05715398","created_at":"2023-02-08T18:00:07.082Z","updated_at":"2024-07-02T16:35:55.802Z","phase":"Phase 1/2","brief_title":"BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05715398","lead_sponsor":"Shanghai Gopherwood Biotech Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • BR790"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-02-10"},{"id":"243efccb-300c-4ed6-9b43-4e854952fa8d","acronym":"SHARP","url":"https://clinicaltrials.gov/study/NCT05701176","created_at":"2023-01-27T17:59:53.242Z","updated_at":"2024-07-02T16:35:56.876Z","phase":"","brief_title":"A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05701176 - SHARP","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression • ALK mutation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression • ALK mutation • EGFR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-01-27"},{"id":"a9582e3e-99d1-4d84-a6a1-43c23c55626e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05647330","created_at":"2022-12-12T15:00:26.571Z","updated_at":"2024-07-02T16:35:59.264Z","phase":"Phase 2","brief_title":"Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05647330","lead_sponsor":"Henan Cancer Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation • EGFR negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • hydroxychloroquine • chloroquine phosphate"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2022-12-12"},{"id":"3d8d662e-91a0-4d37-9933-f2e2052d2ee8","acronym":"CAPAP-lung","url":"https://clinicaltrials.gov/study/NCT04459078","created_at":"2021-01-18T21:26:31.066Z","updated_at":"2024-07-02T16:35:59.705Z","phase":"Phase 2","brief_title":"Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma","source_id_and_acronym":"NCT04459078 - CAPAP-lung","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK mutation • EGFR negative • EGFR mutation + ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • EGFR negative • EGFR mutation + ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/26/2020","start_date":" 08/26/2020","primary_txt":" Primary completion: 05/15/2023","primary_completion_date":" 05/15/2023","study_txt":" Completion: 07/15/2023","study_completion_date":" 07/15/2023","last_update_posted":"2022-12-02"},{"id":"4465b15f-e650-40db-95ec-d8d83a386576","acronym":"","url":"https://clinicaltrials.gov/study/NCT05344976","created_at":"2022-04-25T21:58:14.342Z","updated_at":"2024-07-02T16:36:11.525Z","phase":"Phase 1","brief_title":"MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05344976","lead_sponsor":"Peking University","biomarkers":" EGFR • ALK • MET • ROS1 • MSLN","pipe":" | ","alterations":" ALK positive • EGFR positive • EGFR negative • MSLN positive","tags":["EGFR • ALK • MET • ROS1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • EGFR positive • EGFR negative • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YTS105"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2022-04-25"},{"id":"5a4b2ecc-3279-49c1-9adc-d82e012a73fc","acronym":"BGB-A317-2020","url":"https://clinicaltrials.gov/study/NCT04865705","created_at":"2021-04-29T11:55:41.386Z","updated_at":"2024-07-02T16:36:31.011Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer","source_id_and_acronym":"NCT04865705 - BGB-A317-2020","lead_sponsor":"West China Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK mutation • ROS1 fusion • EGFR negative","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • ROS1 fusion • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 12/10/2021","primary_completion_date":" 12/10/2021","study_txt":" Completion: 06/10/2022","study_completion_date":" 06/10/2022","last_update_posted":"2021-04-29"},{"id":"ba275062-fc61-4841-94a2-e806142bb161","acronym":"LungMate-008","url":"https://clinicaltrials.gov/study/NCT04772287","created_at":"2021-02-26T13:55:20.305Z","updated_at":"2024-07-02T16:36:34.011Z","phase":"Phase 3","brief_title":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","source_id_and_acronym":"NCT04772287 - LungMate-008","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK mutation • EGFR negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • Loqtorzi (toripalimab-tpzi) • pemetrexed • vinorelbine tartrate"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 341","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2021-02-26"},{"id":"838eb627-eeb9-4bf0-aa26-8b163052b906","acronym":"","url":"https://clinicaltrials.gov/study/NCT04613804","created_at":"2021-01-19T20:33:07.093Z","updated_at":"2024-07-02T16:36:39.213Z","phase":"Phase 2","brief_title":"Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy","source_id_and_acronym":"NCT04613804","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR negative","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2020-11-03"},{"id":"ff72d9e7-606a-44da-8aeb-8b3b90c17654","acronym":"","url":"https://clinicaltrials.gov/study/NCT04164745","created_at":"2021-01-18T20:19:23.717Z","updated_at":"2024-07-02T16:36:53.671Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04164745","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR negative","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Focus V (anlotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 11/16/2019","start_date":" 11/16/2019","primary_txt":" Primary completion: 11/16/2021","primary_completion_date":" 11/16/2021","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2019-11-15"},{"id":"af084c6c-9a39-4a8f-8cbd-dca21be3b771","acronym":"ACWDVDFPTAN","url":"https://clinicaltrials.gov/study/NCT03726736","created_at":"2021-01-18T18:15:39.477Z","updated_at":"2024-07-02T16:36:59.013Z","phase":"Phase 1/2","brief_title":"Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC","source_id_and_acronym":"NCT03726736 - ACWDVDFPTAN","lead_sponsor":"Yong Fang","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR negative","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Focus V (anlotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 97","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2019-06-07"},{"id":"9aa9e787-8d6f-48fe-ae8c-fa46af60ddc4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03768037","created_at":"2021-01-18T18:38:38.602Z","updated_at":"2024-07-02T16:37:04.840Z","phase":"Phase 4","brief_title":"Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (\u003e=70) or PS=2 Non-squamous NSCLC","source_id_and_acronym":"NCT03768037","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" EGFR • ROS1","pipe":" | ","alterations":" EGFR negative","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • pemetrexed"],"overall_status":"Unknown status","enrollment":" Enrollment 106","initiation":"Initiation: 11/26/2018","start_date":" 11/26/2018","primary_txt":" Primary completion: 11/26/2019","primary_completion_date":" 11/26/2019","study_txt":" Completion: 11/26/2020","study_completion_date":" 11/26/2020","last_update_posted":"2018-12-07"},{"id":"db5d3c42-74f7-4269-aad0-347155f5e0be","acronym":"","url":"https://clinicaltrials.gov/study/NCT03728374","created_at":"2021-01-18T18:16:05.309Z","updated_at":"2024-07-02T16:37:05.616Z","phase":"Phase 2","brief_title":"Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma","source_id_and_acronym":"NCT03728374","lead_sponsor":"First Affiliated Hospital of Wenzhou Medical University","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR negative","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 38","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2018-11-02"},{"id":"73c48ed5-871f-4631-b9df-472333bf02ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03672136","created_at":"2021-01-18T18:00:46.488Z","updated_at":"2024-07-02T16:37:06.871Z","phase":"Phase 2","brief_title":"Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients","source_id_and_acronym":"NCT03672136","lead_sponsor":"Shandong Cancer Hospital and Institute","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement • EGFR negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 25","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2018-09-14"}]